← All trials
NCT04628026
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 30, 2021
- Primary completion
- Feb 1, 2025
- Completion date
- Feb 1, 2031
- First posted
- Nov 13, 2020
- Last posted
- Sep 29, 2021
- Enrollment
- 650
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of UlmLead sponsor
- University of UlmReponsible party - principal investigator
- University of UlmOverall official - principal investigator
- HOVON - Dutch Haemato-Oncology AssociationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.